125 related articles for article (PubMed ID: 12154013)
1. Angiotensin II type I antagonist prevents pulmonary metastasis of murine renal cancer by inhibiting tumor angiogenesis.
Miyajima A; Kosaka T; Asano T; Asano T; Seta K; Kawai T; Hayakawa M
Cancer Res; 2002 Aug; 62(15):4176-9. PubMed ID: 12154013
[TBL] [Abstract][Full Text] [Related]
2. Functional expression of the angiotensin II type 1 receptor in human ovarian carcinoma cells and its blockade therapy resulting in suppression of tumor invasion, angiogenesis, and peritoneal dissemination.
Suganuma T; Ino K; Shibata K; Kajiyama H; Nagasaka T; Mizutani S; Kikkawa F
Clin Cancer Res; 2005 Apr; 11(7):2686-94. PubMed ID: 15814650
[TBL] [Abstract][Full Text] [Related]
3. Angiotensin II type 1 receptor antagonist as an angiogenic inhibitor in prostate cancer.
Kosaka T; Miyajima A; Takayama E; Kikuchi E; Nakashima J; Ohigashi T; Asano T; Sakamoto M; Okita H; Murai M; Hayakawa M
Prostate; 2007 Jan; 67(1):41-9. PubMed ID: 17044086
[TBL] [Abstract][Full Text] [Related]
4. Blockade of angiotensin AT1a receptor signaling reduces tumor growth, angiogenesis, and metastasis.
Fujita M; Hayashi I; Yamashina S; Itoman M; Majima M
Biochem Biophys Res Commun; 2002 Jun; 294(2):441-7. PubMed ID: 12051731
[TBL] [Abstract][Full Text] [Related]
5. Angiotensin II type 1 receptor antagonist candesartan as an angiogenic inhibitor in a xenograft model of bladder cancer.
Kosugi M; Miyajima A; Kikuchi E; Horiguchi Y; Murai M
Clin Cancer Res; 2006 May; 12(9):2888-93. PubMed ID: 16675585
[TBL] [Abstract][Full Text] [Related]
6. The tumor suppressive effect of angiotensin II type 1 receptor antagonist in a murine osteosarcoma model.
Wasa J; Sugiura H; Kozawa E; Kohyama K; Yamada K; Taguchi O
Anticancer Res; 2011 Jan; 31(1):123-7. PubMed ID: 21273589
[TBL] [Abstract][Full Text] [Related]
7. Blockade of an angiotensin type I receptor enhances effects of radiation on tumor growth and tumor-associated angiogenesis by reducing vascular endothelial growth factor expression.
Ohnuma Y; Toda M; Fujita M; Hosono K; Suzuki T; Ogawa Y; Amano H; Kitasato H; Hayakawa K; Majima M
Biomed Pharmacother; 2009 Feb; 63(2):136-45. PubMed ID: 18691848
[TBL] [Abstract][Full Text] [Related]
8. Angiotensin II type 1 receptor antagonists inhibit cell proliferation and angiogenesis in breast cancer.
Chen X; Meng Q; Zhao Y; Liu M; Li D; Yang Y; Sun L; Sui G; Cai L; Dong X
Cancer Lett; 2013 Jan; 328(2):318-24. PubMed ID: 23092556
[TBL] [Abstract][Full Text] [Related]
9. Candesartan attenuates angiogenesis in hepatocellular carcinoma via downregulating AT1R/VEGF pathway.
Fan F; Tian C; Tao L; Wu H; Liu Z; Shen C; Jiang G; Lu Y
Biomed Pharmacother; 2016 Oct; 83():704-711. PubMed ID: 27470571
[TBL] [Abstract][Full Text] [Related]
10. Angiotensin II type 1 receptor antagonist enhances cis-dichlorodiammineplatinum-induced cytotoxicity in mouse xenograft model of bladder cancer.
Kosugi M; Miyajima A; Kikuchi E; Kosaka T; Horiguchi Y; Murai M; Oya M
Urology; 2009 Mar; 73(3):655-60. PubMed ID: 19167032
[TBL] [Abstract][Full Text] [Related]
11. Angiotensin type 1a receptor signaling-dependent induction of vascular endothelial growth factor in stroma is relevant to tumor-associated angiogenesis and tumor growth.
Fujita M; Hayashi I; Yamashina S; Fukamizu A; Itoman M; Majima M
Carcinogenesis; 2005 Feb; 26(2):271-9. PubMed ID: 15637093
[TBL] [Abstract][Full Text] [Related]
12. Effects of candesartan on angiotensin II-induced renal vasoconstriction in rats and mice.
Ruan X; Purdy KE; Oliverio MI; Coffman TM; Arendshorst WJ
J Am Soc Nephrol; 1999 Jan; 10 Suppl 11():S202-7. PubMed ID: 9892164
[TBL] [Abstract][Full Text] [Related]
13. Renin-angiotensin system dependence of renal hemodynamics in mice.
Traynor TR; Schnermann J
J Am Soc Nephrol; 1999 Jan; 10 Suppl 11():S184-8. PubMed ID: 9892161
[TBL] [Abstract][Full Text] [Related]
14. Effect of angiotensin II type 1 receptor antagonist on tumor growth and angiogenesis in a xenograft model of human bladder cancer.
Kosugi M; Miyajima A; Kikuchi E; Kosaka T; Horiguchi Y; Murai M
Hum Cell; 2007 Feb; 20(1):1-9. PubMed ID: 17506771
[TBL] [Abstract][Full Text] [Related]
15. Candesartan, an angiotensin II type 1 receptor antagonist, inhibits pathological retinal neovascularization by downregulating VEGF receptor-2 expression.
Nakamura S; Tsuruma K; Shimazawa M; Hara H
Eur J Pharmacol; 2012 Jun; 685(1-3):8-14. PubMed ID: 22543084
[TBL] [Abstract][Full Text] [Related]
16. Antagonism of the renin-angiotensin system can counteract cardiac angiogenic vascular endothelial growth factor gene therapy and myocardial angiogenesis in the normal heart.
Siddiqui AJ; Mansson-Broberg A; Gustafsson T; Grinnemo KH; Dellgren G; Hao X; Fischer H; Sylvén C
Am J Hypertens; 2005 Oct; 18(10):1347-52. PubMed ID: 16202860
[TBL] [Abstract][Full Text] [Related]
17. Angiotensin II type 1 receptor blockade prevents up-regulation of angiotensin II type 1A receptors in rat injured artery.
Tazawa S; Nakane T; Chiba S
J Pharmacol Exp Ther; 1999 Feb; 288(2):898-904. PubMed ID: 9918604
[TBL] [Abstract][Full Text] [Related]
18. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
[TBL] [Abstract][Full Text] [Related]
19. Involvement of angiotensin II in cardiovascular and renal injury: effects of an AT1-receptor antagonist on gene expression and the cellular phenotype.
Kim S; Iwao H
J Hypertens Suppl; 1997 Dec; 15(6):S3-7. PubMed ID: 9493120
[TBL] [Abstract][Full Text] [Related]
20. Inhibitory effects of candesartan on responses to angiotensin peptides in the hindquarters vascular bed of the cat.
Lambert DG; Champion HC; Kadowitz PJ
Can J Physiol Pharmacol; 1998 Feb; 76(2):133-40. PubMed ID: 9635151
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
